Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

Biological activity of doubly modified salinomycin analogs - Evaluation in vitro and ex vivo.

Antoszczak M, Urbaniak A, Delgado M, Maj E, Borgström B, Wietrzyk J, Huczyński A, Yuan Y, Chambers TC, Strand D.

Eur J Med Chem. 2018 Aug 5;156:510-523. doi: 10.1016/j.ejmech.2018.07.021. Epub 2018 Jul 10.

PMID:
30025346
2.

Microtubules play an essential role in the survival of primary acute lymphoblastic leukemia cells advancing through G1 phase.

Delgado M, Chambers TC.

Cell Cycle. 2018;17(14):1784-1796. doi: 10.1080/15384101.2018.1496746. Epub 2018 Jul 31.

PMID:
29995568
3.

Salinomycin derivatives exhibit activity against primary acute lymphoblastic leukemia (ALL) cells in vitro.

Urbaniak A, Delgado M, Antoszczak M, Huczyński A, Chambers TC.

Biomed Pharmacother. 2018 Mar;99:384-390. doi: 10.1016/j.biopha.2018.01.081.

PMID:
29367107
4.

Small peptide substrates and high resolution peptide gels for the analysis of site-specific protein phosphorylation and dephosphorylation.

Battle LJ, Chambers TC.

J Biol Methods. 2017;4(3). pii: e76. doi: 10.14440/jbm.2017.199. Epub 2017 Aug 2.

5.

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation.

Delgado M, Kothari A, Hittelman WN, Chambers TC.

J Vis Exp. 2017 Nov 10;(129). doi: 10.3791/56418.

PMID:
29155772
6.

Activity of resveratrol triesters against primary acute lymphoblastic leukemia cells.

Urbaniak A, Delgado M, Kacprzak K, Chambers TC.

Bioorg Med Chem Lett. 2017 Jun 15;27(12):2766-2770. doi: 10.1016/j.bmcl.2017.04.066. Epub 2017 May 9.

PMID:
28499732
7.

Mitotic arrest-induced phosphorylation of Mcl-1 revisited using two-dimensional gel electrophoresis and phosphoproteomics: nine phosphorylation sites identified.

Chu R, Alford SE, Hart K, Kothari A, Mackintosh SG, Kovak MR, Chambers TC.

Oncotarget. 2016 Nov 29;7(48):78958-78970. doi: 10.18632/oncotarget.12586.

8.

Cell Cycle-Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells.

Kothari A, Hittelman WN, Chambers TC.

Cancer Res. 2016 Jun 15;76(12):3553-61. doi: 10.1158/0008-5472.CAN-15-2104. Epub 2016 May 6.

9.

CDK1/2 toolbox in need of an upgrade.

Kothari A, Chambers TC.

Cell Cycle. 2016 Jul 2;15(13):1663-4. doi: 10.1080/15384101.2016.1176399. Epub 2016 Apr 22. No abstract available.

10.

BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.

Alford SE, Kothari A, Loeff FC, Eichhorn JM, Sakurikar N, Goselink HM, Saylors RL, Jedema I, Falkenburg JH, Chambers TC.

Cancer Res. 2015 Apr 1;75(7):1366-75. doi: 10.1158/0008-5472.CAN-14-1849. Epub 2015 Feb 3.

11.

Cyclin B1 overexpression induces cell death independent of mitotic arrest.

Eichhorn JM, Kothari A, Chambers TC.

PLoS One. 2014 Nov 21;9(11):e113283. doi: 10.1371/journal.pone.0113283. eCollection 2014. Erratum in: PLoS One. 2015;10(2):e0117624.

12.

Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.

Eichhorn JM, Alford SE, Sakurikar N, Chambers TC.

Exp Cell Res. 2014 Apr 1;322(2):415-24. doi: 10.1016/j.yexcr.2014.02.010. Epub 2014 Feb 17.

13.

Purported Mcl-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for Mcl-1-dependent cell lines.

Eichhorn JM, Alford SE, Hughes CC, Fenical W, Chambers TC.

Cell Death Dis. 2013 Oct 24;4:e880. doi: 10.1038/cddis.2013.411. No abstract available.

14.

Identification of a mitotic death signature in cancer cell lines.

Sakurikar N, Eichhorn JM, Alford SE, Chambers TC.

Cancer Lett. 2014 Feb 28;343(2):232-8. doi: 10.1016/j.canlet.2013.09.036. Epub 2013 Oct 4.

15.

Critical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic death.

Eichhorn JM, Sakurikar N, Alford SE, Chu R, Chambers TC.

Cell Death Dis. 2013 Oct 3;4:e834. doi: 10.1038/cddis.2013.360.

16.

Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use.

Pawlowska M, Chu R, Fedejko-Kap B, Augustin E, Mazerska Z, Radominska-Pandya A, Chambers TC.

Drug Metab Dispos. 2013 Feb;41(2):414-21. doi: 10.1124/dmd.112.047811. Epub 2012 Nov 16.

17.

Cyclin-dependent kinase-1 (Cdk1)/cyclin B1 dictates cell fate after mitotic arrest via phosphoregulation of antiapoptotic Bcl-2 proteins.

Sakurikar N, Eichhorn JM, Chambers TC.

J Biol Chem. 2012 Nov 9;287(46):39193-204. doi: 10.1074/jbc.M112.391854. Epub 2012 Sep 10.

18.

Cdk1/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of Mcl-1, promoting its degradation and freeing Bak from sequestration.

Chu R, Terrano DT, Chambers TC.

Biochem Pharmacol. 2012 Jan 15;83(2):199-206. doi: 10.1016/j.bcp.2011.10.008. Epub 2011 Oct 18.

19.

Pegylated IFN-α sensitizes melanoma cells to chemotherapy and causes premature senescence in endothelial cells by IRF-1 mediated signaling.

Upreti M, Koonce NA, Hennings L, Chambers TC, Griffin RJ.

Cell Death Dis. 2010;1:e67. doi: 10.1038/cddis.2010.43.

20.

Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis.

Terrano DT, Upreti M, Chambers TC.

Mol Cell Biol. 2010 Feb;30(3):640-56. doi: 10.1128/MCB.00882-09. Epub 2009 Nov 16.

Supplemental Content

Loading ...
Support Center